ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Video Kinematics Predict Donor Heart Function 11/01/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded November 01, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure with reduced ejection fraction and pressure-volume hemodynamics. Key takeaway: Video Kinematics Predict Donor Heart Function.
Article Links:
Article 1: Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. (Journal of the American College of Cardiology)
Article 2: A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension. (JACC. Heart failure)
Article 3: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure. (JACC. Heart failure)
Article 4: Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced. (JACC. Heart failure)
Article 5: Video kinematics of an unloaded, ex-vivo beating heart can predict future loaded heart function. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/video-kinematics-predict-donor-heart-function-11-01-25/
Featured Articles
Article 1: Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41171219
Summary: The 2025 American College of Cardiology Concise Clinical Guidance addresses the evaluation and management of transthyretin cardiac amyloidosis, a growing cause of heart failure, especially in older individuals. It highlights the increased recognition of this condition, particularly in patients presenting with musculoskeletal issues like bilateral carpal tunnel syndrome or spinal stenosis. The guidance emphasizes substantial advances in noninvasive diagnostic capabilities that allow for accurate identification of transthyretin cardiac amyloidosis. These developments are crucial for improving timely diagnosis and guiding effective management strategies for heart failure patients.
Article 2: A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41171248
Summary: This study developed a novel artificial intelligence-based computational pipeline designed to estimate load-independent right ventricular functional indices in patients with pulmonary hypertension. The method utilizes a pressure-time waveform and stroke volume data obtained from clinical right-sided heart catheterization. The objective was to simplify the acquisition of these crucial prognostic indicators for right ventricular dysfunction. This advancement has the potential to integrate these valuable metrics into everyday practice, improving prognostication and management for patients with pulmonary hypertension.
Article 3: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41171251
Summary: This Phase 2, randomized, double-blind, placebo-controlled study investigates C.R.D.-740, an oral phosphodiesterase nine inhibitor, in patients with chronic heart failure with reduced ejection fraction. The study’s primary objective is to assess C.R.D.-740’s effects on plasma and urinary cyclic guanosine monophosphate levels. By inhibiting phosphodiesterase nine, the drug aims to increase intracellular cyclic guanosine monophosphate signaling, thereby enhancing beneficial natriuretic peptide receptor activation. This research explores a novel pharmacological strategy that could potentially improve treatment outcomes for individuals with heart failure with reduced ejection fraction.
Article 4: Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41171249
Summary: This study analyzed data from the EMPEROR-Reduced trial to investigate the association between serum magnesium levels and clinical outcomes in patients with heart failure with reduced ejection fraction. A secondary objective was to determine the influence of the sodium-glucose cotransporter two inhibitor empagliflozin on serum magnesium concentrations. This research addresses existing data limitations regarding magnesium derangements in heart failure with reduced ejection fraction and their clinical implications. The findings contribute to a deeper understanding of patient prognosis and the pleiotropic effects of empagliflozin in this cardiac population.
Article 5: Video kinematics of an unloaded, ex-vivo beating heart can predict future loaded heart function.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40716473
Summary: This study aimed to determine if ex-vivo video kinematics of unloaded beating hearts could predict future loaded heart function, identifying hearts at high risk for primary graft dysfunction. Researchers re-animated porcine hearts procured through a donation after circulatory death protocol in an unloaded ex-situ heart perfusion system. Using five-second cell phone videos and newly developed machine learning software, the study established that these video kinematics can indeed predict post-implant heart performance. This innovative method provides a potential biomarker for donor heart assessment, which could significantly improve donor heart selection and reduce primary graft dysfunction in transplantation.
Transcript
Today’s date is November 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. The 2025 American College of Cardiology Concise Clinical Guidance addresses the evaluation and management of transthyretin cardiac amyloidosis, a growing cause of heart failure, especially in older individuals. It highlights the increased recognition of this condition, particularly in patients presenting with musculoskeletal issues like bilateral carpal tunnel syndrome or spinal stenosis. The guidance emphasizes substantial advances in noninvasive diagnostic capabilities that allow for accurate identification of transthyretin cardiac amyloidosis. These developments are crucial for improving timely diagnosis and guiding effective management strategies for heart failure patients.
Article number two. A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension. This study developed a novel artificial intelligence-based computational pipeline designed to estimate load-independent right ventricular functional indices in patients with pulmonary hypertension. The method utilizes a pressure-time waveform and stroke volume data obtained from clinical right-sided heart catheterization. The objective was to simplify the acquisition of these crucial prognostic indicators for right ventricular dysfunction. This advancement has the potential to integrate these valuable metrics into everyday practice, improving prognostication and management for patients with pulmonary hypertension.
Article number three. Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure. This Phase 2, randomized, double-blind, placebo-controlled study investigates C.R.D.-740, an oral phosphodiesterase nine inhibitor, in patients with chronic heart failure with reduced ejection fraction. The study’s primary objective is to assess C.R.D.-740’s effects on plasma and urinary cyclic guanosine monophosphate levels. By inhibiting phosphodiesterase nine, the drug aims to increase intracellular cyclic guanosine monophosphate signaling, thereby enhancing beneficial natriuretic peptide receptor activation. This research explores a novel pharmacological strategy that could potentially improve treatment outcomes for individuals with heart failure with reduced ejection fraction.
Article number four. Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced. This study analyzed data from the EMPEROR-Reduced trial to investigate the association between serum magnesium levels and clinical outcomes in patients with heart failure with reduced ejection fraction. A secondary objective was to determine the influence of the sodium-glucose cotransporter two inhibitor empagliflozin on serum magnesium concentrations. This research addresses existing data limitations regarding magnesium derangements in heart failure with reduced ejection fraction and their clinical implications. The findings contribute to a deeper understanding of patient prognosis and the pleiotropic effects of empagliflozin in this cardiac population.
Article number five. Video kinematics of an unloaded, ex-vivo beating heart can predict future loaded heart function. This study aimed to determine if ex-vivo video kinematics of unloaded beating hearts could predict future loaded heart function, identifying hearts at high risk for primary graft dysfunction. Researchers re-animated porcine hearts procured through a donation after circulatory death protocol in an unloaded ex-situ heart perfusion system. Using five-second cell phone videos and newly developed machine learning software, the study established that these video kinematics can indeed predict post-implant heart performance. This innovative method provides a potential biomarker for donor heart assessment, which could significantly improve donor heart selection and reduce primary graft dysfunction in transplantation.
Thank you for listening. Don’t forget to subscribe.
Keywords
heart failure with reduced ejection fraction, pressure-volume hemodynamics, primary graft dysfunction, pulmonary hypertension, EMPEROR-Reduced trial, spinal stenosis, artificial intelligence, sodium-glucose cotransporter two inhibitors, C.R.D.-740, ex-situ heart perfusion, cyclic guanosine monophosphate, heart failure, carpal tunnel syndrome, natriuretic peptides, right ventricular dysfunction, machine learning, ex-vivo video kinematics, noninvasive diagnosis, phosphodiesterase nine inhibitor, empagliflozin, heart transplantation, right-sided heart catheterization, transthyretin cardiac amyloidosis, serum magnesium.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Video Kinematics Predict Donor Heart Function 11/01/25 first appeared on Cardiology Today.
Article Links:
Article 1: Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. (Journal of the American College of Cardiology)
Article 2: A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension. (JACC. Heart failure)
Article 3: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure. (JACC. Heart failure)
Article 4: Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced. (JACC. Heart failure)
Article 5: Video kinematics of an unloaded, ex-vivo beating heart can predict future loaded heart function. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/video-kinematics-predict-donor-heart-function-11-01-25/
Featured Articles
Article 1: Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41171219
Summary: The 2025 American College of Cardiology Concise Clinical Guidance addresses the evaluation and management of transthyretin cardiac amyloidosis, a growing cause of heart failure, especially in older individuals. It highlights the increased recognition of this condition, particularly in patients presenting with musculoskeletal issues like bilateral carpal tunnel syndrome or spinal stenosis. The guidance emphasizes substantial advances in noninvasive diagnostic capabilities that allow for accurate identification of transthyretin cardiac amyloidosis. These developments are crucial for improving timely diagnosis and guiding effective management strategies for heart failure patients.
Article 2: A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41171248
Summary: This study developed a novel artificial intelligence-based computational pipeline designed to estimate load-independent right ventricular functional indices in patients with pulmonary hypertension. The method utilizes a pressure-time waveform and stroke volume data obtained from clinical right-sided heart catheterization. The objective was to simplify the acquisition of these crucial prognostic indicators for right ventricular dysfunction. This advancement has the potential to integrate these valuable metrics into everyday practice, improving prognostication and management for patients with pulmonary hypertension.
Article 3: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41171251
Summary: This Phase 2, randomized, double-blind, placebo-controlled study investigates C.R.D.-740, an oral phosphodiesterase nine inhibitor, in patients with chronic heart failure with reduced ejection fraction. The study’s primary objective is to assess C.R.D.-740’s effects on plasma and urinary cyclic guanosine monophosphate levels. By inhibiting phosphodiesterase nine, the drug aims to increase intracellular cyclic guanosine monophosphate signaling, thereby enhancing beneficial natriuretic peptide receptor activation. This research explores a novel pharmacological strategy that could potentially improve treatment outcomes for individuals with heart failure with reduced ejection fraction.
Article 4: Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41171249
Summary: This study analyzed data from the EMPEROR-Reduced trial to investigate the association between serum magnesium levels and clinical outcomes in patients with heart failure with reduced ejection fraction. A secondary objective was to determine the influence of the sodium-glucose cotransporter two inhibitor empagliflozin on serum magnesium concentrations. This research addresses existing data limitations regarding magnesium derangements in heart failure with reduced ejection fraction and their clinical implications. The findings contribute to a deeper understanding of patient prognosis and the pleiotropic effects of empagliflozin in this cardiac population.
Article 5: Video kinematics of an unloaded, ex-vivo beating heart can predict future loaded heart function.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40716473
Summary: This study aimed to determine if ex-vivo video kinematics of unloaded beating hearts could predict future loaded heart function, identifying hearts at high risk for primary graft dysfunction. Researchers re-animated porcine hearts procured through a donation after circulatory death protocol in an unloaded ex-situ heart perfusion system. Using five-second cell phone videos and newly developed machine learning software, the study established that these video kinematics can indeed predict post-implant heart performance. This innovative method provides a potential biomarker for donor heart assessment, which could significantly improve donor heart selection and reduce primary graft dysfunction in transplantation.
Transcript
Today’s date is November 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. The 2025 American College of Cardiology Concise Clinical Guidance addresses the evaluation and management of transthyretin cardiac amyloidosis, a growing cause of heart failure, especially in older individuals. It highlights the increased recognition of this condition, particularly in patients presenting with musculoskeletal issues like bilateral carpal tunnel syndrome or spinal stenosis. The guidance emphasizes substantial advances in noninvasive diagnostic capabilities that allow for accurate identification of transthyretin cardiac amyloidosis. These developments are crucial for improving timely diagnosis and guiding effective management strategies for heart failure patients.
Article number two. A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension. This study developed a novel artificial intelligence-based computational pipeline designed to estimate load-independent right ventricular functional indices in patients with pulmonary hypertension. The method utilizes a pressure-time waveform and stroke volume data obtained from clinical right-sided heart catheterization. The objective was to simplify the acquisition of these crucial prognostic indicators for right ventricular dysfunction. This advancement has the potential to integrate these valuable metrics into everyday practice, improving prognostication and management for patients with pulmonary hypertension.
Article number three. Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure. This Phase 2, randomized, double-blind, placebo-controlled study investigates C.R.D.-740, an oral phosphodiesterase nine inhibitor, in patients with chronic heart failure with reduced ejection fraction. The study’s primary objective is to assess C.R.D.-740’s effects on plasma and urinary cyclic guanosine monophosphate levels. By inhibiting phosphodiesterase nine, the drug aims to increase intracellular cyclic guanosine monophosphate signaling, thereby enhancing beneficial natriuretic peptide receptor activation. This research explores a novel pharmacological strategy that could potentially improve treatment outcomes for individuals with heart failure with reduced ejection fraction.
Article number four. Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced. This study analyzed data from the EMPEROR-Reduced trial to investigate the association between serum magnesium levels and clinical outcomes in patients with heart failure with reduced ejection fraction. A secondary objective was to determine the influence of the sodium-glucose cotransporter two inhibitor empagliflozin on serum magnesium concentrations. This research addresses existing data limitations regarding magnesium derangements in heart failure with reduced ejection fraction and their clinical implications. The findings contribute to a deeper understanding of patient prognosis and the pleiotropic effects of empagliflozin in this cardiac population.
Article number five. Video kinematics of an unloaded, ex-vivo beating heart can predict future loaded heart function. This study aimed to determine if ex-vivo video kinematics of unloaded beating hearts could predict future loaded heart function, identifying hearts at high risk for primary graft dysfunction. Researchers re-animated porcine hearts procured through a donation after circulatory death protocol in an unloaded ex-situ heart perfusion system. Using five-second cell phone videos and newly developed machine learning software, the study established that these video kinematics can indeed predict post-implant heart performance. This innovative method provides a potential biomarker for donor heart assessment, which could significantly improve donor heart selection and reduce primary graft dysfunction in transplantation.
Thank you for listening. Don’t forget to subscribe.
Keywords
heart failure with reduced ejection fraction, pressure-volume hemodynamics, primary graft dysfunction, pulmonary hypertension, EMPEROR-Reduced trial, spinal stenosis, artificial intelligence, sodium-glucose cotransporter two inhibitors, C.R.D.-740, ex-situ heart perfusion, cyclic guanosine monophosphate, heart failure, carpal tunnel syndrome, natriuretic peptides, right ventricular dysfunction, machine learning, ex-vivo video kinematics, noninvasive diagnosis, phosphodiesterase nine inhibitor, empagliflozin, heart transplantation, right-sided heart catheterization, transthyretin cardiac amyloidosis, serum magnesium.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Video Kinematics Predict Donor Heart Function 11/01/25 first appeared on Cardiology Today.
More episodes of the podcast Cardiology Today
Nup35 Controls Heart Remodeling 10/28/25
28/10/2025
In God we trust